Press Releases Investors Overview News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts Company Info Overview Management Team Clinical Advisory Board Medical Consultants Presentations Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Investor Tools Email Alerts Tear Sheet Investor Presentation Contacts RSS News Feed News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 All Releases Financial Releases Viveve to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference Mar 2, 2021 Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020 Feb 18, 2021 Viveve Recognized for Leadership in Appointing Women to Board of Directors Feb 9, 2021 Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent Feb 2, 2021 Viveve Regulatory Executive Named Among Top 25 Women Leaders in Medical Devices Jan 28, 2021 Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence Jan 21, 2021 Viveve Announces Closing of an Upsized $27.6 Million Underwritten Public Offering and Exercise of Over-Allotment Option Jan 19, 2021 Viveve Announces Pricing of Upsized $24 Million Underwritten Public Offering Jan 14, 2021 Viveve Regains Compliance with NASDAQ Continued Listing Rules Dec 17, 2020 Viveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial Protocol Dec 10, 2020 1 2 3 4 5 6 7 8 9 10 ...31
Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence Jan 21, 2021
Viveve Announces Closing of an Upsized $27.6 Million Underwritten Public Offering and Exercise of Over-Allotment Option Jan 19, 2021
Viveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial Protocol Dec 10, 2020
